Ignacio Gil Bazo-rekin lankidetzan egindako argitalpenak (85)

2024

  1. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. Biología celular del cáncer

    Biología celular biomédica (Elsevier), pp. 375-407

  3. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

    Journal of Translational Medicine, Vol. 21, Núm. 1

  4. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. Impact on the Nutritional Status and Inflammation of Patients with Cancer Hospitalized after the SARS-CoV-2 Lockdown

    Nutrients, Vol. 14, Núm. 13

  3. MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

    European Journal of Cancer, Vol. 174, pp. S122

2021

  1. Delta-radiomics signature for prediction of survival in advanced nsclc patients treated with immunotherapy

    Proceedings - International Symposium on Biomedical Imaging

2020

  1. Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?

    Journal of Thoracic Oncology

  2. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

  3. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

  4. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice

    Clinical Cancer Research, Vol. 26, Núm. 16, pp. 4186-4197

  5. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

  6. Repeated stereotactic radiosurgery for recurrent brain metastases: An effective strategy to control intracranial oligometastatic disease

    Critical Reviews in Oncology/Hematology, Vol. 153

  7. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Thorax, Vol. 74, Núm. 4, pp. 371-379

  2. Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies

    TH Open

  3. Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809

  4. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638